- Firm initiates Fibrocell Science (NASDAQ:FCSC) with a Buy rating and $14 price target (implied upside 165%).
- "Leaning on 20 years of experience with autologous cell therapy, Fibrocell is establishing leadership for the treatment of rare skin and connective tissue disorders," firm says.
- Note: In late September, Wedbush downgraded FCSC to Neutral (PT: $6), saying there is limited upside to the stock over the next year.
- Previously: Pre-clinical data on FCX-007 gives Fibrocell a boost; shares up 16% (Oct. 9)